Filing Details

Accession Number:
0001209191-11-045977
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-08-30 15:44:26
Reporting Period:
2011-08-29
Filing Date:
2011-08-30
Accepted Time:
2011-08-30 15:44:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1256126 Peter Mueller C/O Vertex Pharmaceuticals Incorporated
130 Waverly St
Cambridge MA 02139
Evp, Global R&D, Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-08-29 4,300 $10.41 138,035 No 4 M Direct
Common Stock Acquisiton 2011-08-29 5,200 $11.27 143,235 No 4 M Direct
Common Stock Disposition 2011-08-29 9,500 $45.01 133,735 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Disposition 2011-08-29 4,300 $0.00 4,300 $10.41
Common Stock Stock Options Disposition 2011-08-29 5,200 $0.00 5,200 $11.27
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-02-02 No 4 M Direct
12,800 2014-10-06 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,495 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $45.01 (range $45.00 to $45.26).
  3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Fully vested.